This thread has a Science for ME 'News in Brief' post for each week in May 2024 by a team including @Trish, @Kalliope, @ahimsa and @SNT Gatchaman....

We have been given the green light for our new scan tracking leukocyte infiltration of the brain. We can now run the first-ever patient! I wanted to share th...

Since 1969, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has been classified as a neurological disease in the International Classification of Diseases by the World Health Organization. Although numerous studies over time have uncovered organic abnormalities in patients with ME/CFS, and the majority of researchers to date classify the disease as organic, many physicians still believe that ME/CFS is a psychosomatic illness. In this article, we show how detrimental this belief is to the care and well-being of affected patients and, as a consequence, how important the education of physicians and the public is to stop misdiagnosis, mistreatment, and stigmatization on the grounds of incorrect psychosomatic attributions about the etiology and clinical course of ME/CFS.

Nearly 20 years after the NHS killed Sophia Mirza, people with ME/CFS are still dying. Why? Why has nothing the ME community done worked?

WASHINGTON, April 9 – Sen. Bernie Sanders (I-Vt.), Chair of the Senate Health, Education, Labor, and...

IntroductionMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) presents substantial challenges in patient care due to its intricate multisystem natu...

A campaign group will target UK media outlets during global ME Awareness Day - calling out what it calls systemic "mis-and-disinformation"

People with Long COVID in Australia have poor health outcomes that are comparable with another emerging disease known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

The notion that this illness is psychosomatic is having devastating effects, says Guardian columnist George Monbiot

Bisher sind es nur Fallberichte über drei Patienten, aber ein aktueller Beitrag über komplette Remissionen von Long-COVID nach dem Einsatz monoklonaler SARS-CoV-2-Antikörper lässt auf einen neuen Ansatz gegen die Langzeitfolgen einer COVID-19-Erkrankung hoffen.